Korro Bio (KRRO) Net Equity Issued and Repurchased (2018 - 2026)

Korro Bio (KRRO) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $83.2 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $83.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.2 million (down 15.69% YoY) and the FY2023 annual result came in at $117.2 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased slipped to $83.2 million in Q1 2026, from $100.0 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $117.2 million in Q4 2023 to a low of -$60000.0 in Q4 2022.
• A 4-year average of $37.6 million and a median of $31000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased slumped 154.55% — and 2023, when it surged 195516.67%.
• Tracing KRRO's Net Equity Issued and Repurchased over 4 years: stood at -$60000.0 in 2022, then surged by 195516.67% to $117.2 million in 2023, then decreased by 14.71% to $100.0 million in 2024, then slipped by 16.85% to $83.2 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $83.2 million (Q1 2026), $100.0 million (Q4 2024), and $117.2 million (Q4 2023), per Business Quant data.